ClinicalTrials.gg
RecruitingNCT05072626Updated Apr 3, 2026

High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia

An observational study in Biliary Atresia, Infant and Nutrition Support, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged Up to 3 Months. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Children's Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
Up to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.

Planned enrollment
4th of 10
300 · median 200
Started
2021
with 3 others
Observational
10 of 21
5 open now
Registered
8th of 21
by date
Lead sponsor
4 of 21
Children's Hospital of Fudan University

Among the 21 studies in Biliary Atresia with a site in China, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2021, is one of 10 observational ones, and was the 8th registered.

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: Up to 3 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Biliary Atresia with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, single center and observational open clinical study.

Read the detailed description

Biliary atresia (BA) is a significant disease leading to liver failure in infancy, with BA accounting for 50% of infant liver transplantation cases. Many BA children experience complications related to malnutrition, particularly during the first year of life. These complications are primarily characterized by reduced muscle mass and structural protein, impaired bone mineralization, diminished fat reserves, and deficiencies in vitamins and trace elements. Some studies have indicated that oral administration of specialized medium-chain triglycerides (MCT) and branched-chain amino acids FSMP with polysaccharides still result in malnutrition and growth retardation among BA children, necessitating enteral nutrition support treatment through tube feeding. The American Association for the Study of Biliary Atresia conducted a study on the prognosis of 104 children with biliary atresia after Kasai surgery across six clinical centers. They found that the key period for changes in growth rate occurred six months post-surgery, with faster-growing children exhibiting better prognoses compared to those with slower growth rates. Active nutritional therapy can enhance the prognosis of children with biliary atresia, particularly before and after Kasai surgery within the initial six-month period following surgery. Currently, there is no standardized process for using Foods for Special Medical Purpose in China nor any regulations governing the addition and monitoring of trace elements and vitamins. Therefore, this study aims to improve overall outcomes for children with biliary atresia through standardized nutrition assessment procedures as well as education, intervention, and follow-up measures.A total of 300 hospitalized patients were enrolled, all of whom received high MCT formula nutritional support following the Kasai operation, in order to investigate the impact of high MCT formula on the nutritional status and growth of children with biliary atresia after undergoing the Kasai procedure.

03

Conditions studied

  • Biliary Atresia
  • Infant
  • Nutrition Support
  • Medium-chain Triglyceride

Browse trials for

Keywords

  • Biliary Atresia
  • Kasai portoenterostomy
  • Nutrition Support
  • medium-chain triglyceride
04

Who can participate

Ages eligible
Up to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The Kasai procedure for infants with biliary atresia under the age of 3 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The Kasai procedure for infants with biliary atresia under the age of 3 months.

Exclusion criteria

Exclusion Criteria:

  • Complicated with cirrhosis, hepatitis, or other hepatic disorders;
  • Complicated with other systemic serious diseases (such as congenital multiple malformations, chromosome abnormalities)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • high MCT formula nutritional support

    Infants aged 0-3 months who underwent Kasai operation for congenital biliary atresia and were able to receive enteral nutrition through oral or tube feeding were administered a high MCT formula powder + breast milk (with the high MCT formula powder accounting for ≥50%) after the Kasai operation. If breast milk was insufficient, regular formula was used as a substitute. The recommended energy intake was set at 100-130% of DRIs.

06

What researchers measure

Primary outcomes

  1. Z-scores of body weight

    The patient will be weighed in the recumbent position on an electronic infant scale. Z-scores for weight for age (WAZ) were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 3 months after Kasai portoenterostomy

Secondary outcomes

  1. Z-scores of body length

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 1 month after Kasai portoenterostomy

  2. Z-scores of body length

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 3 months after Kasai portoenterostomy

  3. Z-scores of body length

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 6 months after Kasai portoenterostomy

  4. Z-scores of body length

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 1 year after Kasai portoenterostomy

  5. Z-scores of body weight

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 1 month after Kasai portoenterostomy

  6. Z-scores of body weight

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 6 months after Kasai portoenterostomy

  7. Z-scores of body weight

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 1 year after Kasai portoenterostomy

  8. Z-scores of head circumference

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 1 month after Kasai portoenterostomy

  9. Z-scores of head circumference

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 3 months after Kasai portoenterostomy

  10. Z-scores of head circumference

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 6 months after Kasai portoenterostomy

  11. Z-scores of head circumference

    Z-scores were obtained from the World Health Organization Anthro software and WHO Child Growth Standards.

    Time frame: 1 year after Kasai portoenterostomy

  12. level of vitamin A

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  13. level of vitamin A

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  14. level of vitamin A

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  15. level of vitamin A

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  16. level of 25(OH) D

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  17. level of 25(OH) D

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  18. level of 25(OH) D

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  19. level of 25(OH) D

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  20. level of vitamin E

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  21. level of vitamin E

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  22. level of vitamin E

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  23. level of vitamin E

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  24. level of vitamin K

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  25. level of vitamin K

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  26. level of vitamin K

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  27. level of vitamin K

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  28. Aspartate aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  29. Aspartate aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  30. Aspartate aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  31. Aspartate aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  32. Alanine aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  33. Alanine aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  34. Alanine aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  35. Alanine aminotransferase

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  36. Total Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  37. Total Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  38. Total Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  39. Total Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  40. Direct Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  41. Direct Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  42. Direct Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  43. Direct Bilirubin

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  44. Gamma-glutamyl transferase

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  45. Gamma-glutamyl transferase

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  46. Gamma-glutamyl transferase

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  47. Gamma-glutamyl transferase

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  48. Total bile acid

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  49. Total bile acid

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  50. Total bile acid

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  51. Total bile acid

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  52. White blood cell

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  53. White blood cell

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  54. White blood cell

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  55. White blood cell

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  56. lymphocyte

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  57. lymphocyte

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  58. lymphocyte

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  59. lymphocyte

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  60. Neutrophil count

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  61. Neutrophil count

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  62. Neutrophil count

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  63. Neutrophil count

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  64. International Normalized Ratio

    Blood biochemical data are from clinical database.

    Time frame: 1 month after Kasai portoenterostomy

  65. International Normalized Ratio

    Blood biochemical data are from clinical database.

    Time frame: 3 months after Kasai portoenterostomy

  66. International Normalized Ratio

    Blood biochemical data are from clinical database.

    Time frame: 6 months after Kasai portoenterostomy

  67. International Normalized Ratio

    Blood biochemical data are from clinical database.

    Time frame: 1 year after Kasai portoenterostomy

  68. Incidence of postoperative cholangitis

    Data from clinical database

    Time frame: 1 year after Kasai portoenterostomy

  69. Liver transplantation

    Data from clinical database

    Time frame: 1 year after Kasai portoenterostomy

  70. MMP-7

    Data from clinical database

    Time frame: 1 months after Kasai portoenterostomy

  71. MMP-7

    Data from clinical database

    Time frame: 3 months after Kasai portoenterostomy

  72. MMP-7

    Data from clinical database

    Time frame: 6 months after Kasai portoenterostomy

  73. MMP-7

    Data from clinical database

    Time frame: 1 year after Kasai portoenterostomy

  74. Intestinal flora

    Data from clinical database

    Time frame: 1 months after Kasai portoenterostomy

  75. Intestinal flora

    Data from clinical database

    Time frame: 3 months after Kasai portoenterostomy

  76. Intestinal flora

    Data from clinical database

    Time frame: 6 months after Kasai portoenterostomy

  77. Intestinal flora

    Data from clinical database

    Time frame: 1 year after Kasai portoenterostomy

  78. bile acid spectrum

    Data from clinical database

    Time frame: 1 months after Kasai portoenterostomy

  79. bile acid spectrum

    Data from clinical database

    Time frame: 3 months after Kasai portoenterostomy

  80. bile acid spectrum

    Data from clinical database

    Time frame: 6 months after Kasai portoenterostomy

  81. bile acid spectrum

    Data from clinical database

    Time frame: 1 year after Kasai portoenterostomy

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2028, 86 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Oct 11, 2021
StartActual
Oct 11, 2021
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05072626
Responsible party
Qian Tian (Deputy Director of clinical Nutrition, Children's Hospital of Fudan University) — Principal investigator
First posted
Oct 11, 2021
Start date
Oct 11, 2021
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Tian Qian, M.D. PhD
Contact
drqiantian@fudan.edu.cn
+8602164931981
Xiaoyan Gong, Bachelor
Contact
xygongfudan@163.com
+8602164931980
Tian Qian, M.D. PhD
study director · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion